Groningen, The Netherlands, 15 December 2008
Mucosis B.V. and TNO announce flu vaccine research and development partnership.
--> Download the pdf
Dutch biotechnology company Mucosis B.V. and the Netherlands Organization for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop an intranasal influenza vaccine.
Under the agreement, TNO will develop innovative methods for the selection, formulation and manufacturing of linker molecules to attach antigens, such as influenza antigens, to delivery systems like Mucosis’s proprietary MimopathTM system. The linker molecules will be used to formulate Mucosis’s lead product candidate FluGEM™, an intranasal influenza vaccine. The vaccine will be evaluated in influenza challenge models. The collaboration is supported with €1.2 million in a TNO innovative research co-financing initiative.
“We are pleased to work with TNO,” said Govert Schouten, CEO of Mucosis. “ This partnership allows us to benefit from TNO’s biopharmaceutical research, development and manufacturing expertise and will further the development of our FluGEM® vaccine”.
“We are extremely happy that Mucosis has decided to work with TNO on this important new intranasal influenza vaccine” added Menzo Havenga, Managing Director of Biosciences at TNO. “This partnership further strengthens our package of biopharmaceutical development services allowing us to add novel vaccine production technologies and pre-clinical influenza models to our portfolio of biopharmaceutical development services and positions TNO in an extremely important infectious disease area.
For further information please contact:
+31 (6) 55320948
Tel. +31 (30) 6944615
Mob. +31 (6) 23296045
Mucosis B.V. is a Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is FluGEM™, an intranasal vaccine to prevent influenza. Mucosis’s vaccines are based on the patented Mimopath™ technology. This technology enables a more natural immune response as well as a broad base of protection.
About Mimopath® technology
Mimopath® technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed an easy technique to formulate the L.lactis bacteria into non-living particles that can be loaded with antigens from viral, bacterial or parasitic origin. The antigen-covered particles form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.
TNO is a prominent, independent knowledge company whose expertise and research contributes significantly to the competitiveness of businesses and organizations, to the economy and to the quality of life as a whole. Its versatility and capacity to integrate this knowledge makes TNO unique. TNO employs about 4300 professionals. TNO works in five core areas: TNO Quality of Life, TNO Defense, Security and Safety, TNO Science and Industry, TNO Built Environment and Geosciences, TNO Information and Communication Technology.